Successful end of Phase 2 Meeting with FDA
(World News Science)

Mereo BioPharma Group plc (`Mereo` or the `Company` or the `Group`) Mereo Announces Successful End of Phase 2 Meeting with FDA and Provides Outline of Pivotal Trial Design for Acumapimod for Severe Exacerbations of COPD London, 15 April 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces that it has held a successful Type B end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding acumapimod (BCT-197) as a treatment for the reduction of acute exacerbations of COPD (AECOPD). In the meeting, Mereo and the FDA discussed, and agreed in principle, an outline for the design of a pivotal Phase...